Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects an estimated eight million individuals worldwide, predominantly within Latin America, while placing roughly 100 million people at imminent risk of contracting the disease. Despite the availability of curative treatments in the acute phase, the disease often progresses undetected into a chronic stage, where it inflicts severe pathological outcomes, including cardiomyopathy, digestive tract complications, and nervous system disorders. The public health challenge is compounded by socio-economic dynamics, as the disease disproportionately affects marginalized and low-income populations, thereby limiting pharmaceutical investment incentives.

Addressing this disparity, computational chemistry has emerged as a transformative tool in medicinal chemistry, providing a virtual laboratory where molecular interactions and catalytic reactions can be modeled with atomic precision before any physical synthesis occurs. The Kent research team, in particular, focused their efforts on the class of naphthoquinones, compounds already demonstrated to possess potent bioactivity against trypanosomal parasites. By harnessing a ruthenium-based catalytic system, the researchers explored the selective functionalization of these molecules through C–H alkenylation, an approach that strategically modifies molecular structures to optimize pharmacological properties like potency, stability, and selectivity.

To critically evaluate and refine predictive accuracy, the team benchmarked nine prominent quantum-chemical computational approaches against an established, highly precise reference method. This comparative analysis highlighted a particular protocol capable of reproducing complex reaction mechanisms with near-reference-level fidelity. Moreover, they demonstrated that a more computationally economical method, despite lower expenses and faster performance, maintained sufficient mechanistic insight, offering a practical avenue for rapid high-throughput screening of potential drug candidates.

The implications of this development are extensive. Incorporating such validated computational pipelines enables medicinal chemists to focus experimental resources on only the most promising molecular variants, thereby accelerating the iterative cycle of drug optimization. This strategy significantly truncates development timelines and reduces financial burdens, making it particularly relevant for neglected tropical diseases where commercial funding often falls short.

Dr. Felipe Fantuzzi, lead author and Lecturer in Chemistry at the University of Kent’s School of Natural Sciences, underscores the importance of this synergy between computational foresight and experimental validation: “Our protocol does not replace laboratory experiments, but it empowers researchers to prioritize modifications that are most chemically and biologically promising, enhancing efficiency in the discovery pipeline.” This approach exemplifies a paradigm shift towards data-driven drug design, where mechanistic understanding informs and guides empirical efforts.

Furthermore, the study aligns well with the rapid integration of artificial intelligence into pharmaceutical research. While AI excels at detecting patterns and navigating massive chemical spaces, it requires robust, interpretable physical models to ground its predictions. Dr. Fantuzzi details this complementarity: “Physics-based computational chemistry lays the chemical foundation that AI builds upon, ensuring candidate prioritization is both accurate and chemically meaningful.”

This research forms part of the NUBIAN Project, a multinational collaboration linking institutions in the UK, Brazil, and Sierra Leone, with funding support from the Royal Society. The project is dedicated to addressing neglected tropical diseases through interdisciplinary approaches, blending computational innovation with practical medicinal chemistry and parasitology toward impactful therapeutic advancement.

Published in the journal ChemistryOpen, the study titled “Ruthenium-Catalyzed C–H Alkenylation of Trypanocidal Naphthoquinones: A Mechanistic Benchmarking Study” presents a rigorous examination of catalytic transformations central to drug modification strategies, underscoring how theoretical modeling can modernize neglected disease drug development. The article appears on the front cover of the February 2026 issue, marking a milestone in computational and medicinal chemistry collaboration.

This work highlights the critical interplay between catalyst design, reaction mechanism elucidation, and computational precision in advancing drug discovery. The selective C–H alkenylation catalyzed by ruthenium offers a blueprint for controlled structural diversification of biologically active compounds, with potential extension beyond Chagas disease toward other parasitic infections.

As global health challenges deepen, especially in regions burdened by systemic poverty and limited healthcare infrastructure, innovations such as this computational protocol become indispensable. They harness the power of chemical theory and computational efficiency to navigate the complex terrain of drug candidate optimization, ultimately enabling faster, cheaper, and better-targeted treatment options for some of the world’s most vulnerable populations.

By pioneering tools that combine mechanistic rigor with screening speed, Kent researchers have positioned themselves at the forefront of a new generation of drug discovery methodologies. This promising fusion between computational chemistry and catalytic reaction engineering is poised to catalyze novel interventions, transforming neglected tropical disease treatment landscapes with precision and agility.

Subject of Research: Not applicable

Article Title: Ruthenium-Catalyzed C–H Alkenylation of Trypanocidal Naphthoquinones: A Mechanistic Benchmarking Study

News Publication Date: 22-Feb-2026

Web References: https://doi.org/10.1002/open.202500465

References: University of Kent: Esther R. S. Paz, Cauê P. Souza and Felipe Fantuzzi, ChemistryOpen

Keywords:

• Chagas disease
• Computational chemistry
• Chemical modeling
• Artificial intelligence
• Parasitology
• Drug candidates
• Drug discovery
• Drug development

The investigative team conducted an extensive virtual screening of twenty-five compounds derived from Andrographis paniculata, using the Schrödinger Suite 2020 platform to prepare ligands and simulate their binding capabilities against the crystallographic structure of HDAC2. HDAC2, a member of the class I histone deacetylases, plays a critical role in chromatin remodeling and repression of gamma-globin gene expression. Its inhibition can de-repress fetal hemoglobin production, providing therapeutic relief in beta thalassemia. The researchers meticulously prepared the HDAC2 target by removing crystallographic water molecules and optimizing the protein structure for docking simulations.

Upon docking, glide extra precision (XP) mode was employed to enhance the accuracy of ligand-receptor binding predictions, complemented by molecular mechanics/generalized born surface area (MM-GBSA) scoring to estimate binding free energies. Among all candidates, the compound named SRJ09, a derivative of andrographolide, exhibited superior docking scores and favorable binding energies compared to known HDAC2 inhibitors. SRJ09 demonstrated a binding pose within the active site of HDAC2 analogous to that of the reference inhibitor, 20Y, suggesting a comparable or enhanced affinity.

To corroborate the stability and dynamic behavior of the SRJ09-HDAC2 complex, the study extended into molecular dynamics simulations using GROMACS 2019. These simulations, performed over a 5-nanosecond timeframe, utilized the optimized potentials for liquid simulations (OPLS) force field and considered solvation effects with three-site point charge (SPC) water models. The SRJ09-HDAC2 complex remained stable throughout the simulation period, as indicated by consistent root mean square deviation (RMSD) and root mean square fluctuation (RMSF) metrics. This stability under physiological-like conditions strengthens the hypothesis of SRJ09 as a viable HDAC2 inhibitor.

Parallel to binding assessments, absorption, distribution, metabolism, and excretion (ADME) properties were predicted using QikProp software to evaluate the drug-likeness and pharmacokinetic viability of SRJ09. The predictions affirmed that SRJ09 meets critical ADME parameters, including oral bioavailability and metabolic stability, essential for candidate progression in drug development pipelines. This intersection of favorable binding affinity and pharmacokinetic properties substantiates SRJ09’s candidacy as a natural therapeutic molecule.

The choice of Andrographis paniculata as a source of bioactive compounds is compelling given its storied history in traditional medicine. Known for its anti-inflammatory, antibacterial, and antioxidant properties, this plant’s metabolites have attracted scientific interest for pharmaceutical applications. The identification of SRJ09 expands the pharmacological repertoire of Andrographis paniculata, positioning it as a source for epigenetically active compounds targeting hematological diseases.

The research emphasizes the growing prominence of in silico methodologies in drug discovery and development, particularly in hematology. Computational docking and molecular dynamics simulations provide a cost-effective and efficient means to screen bioactive compounds and predict interaction patterns prior to experimental validation. While the findings resonate with promise, the authors prudently underscore the necessity for subsequent experimental steps. In vitro cell-based assays and in vivo animal models are imperative to confirm the therapeutic efficacy, safety, and mechanism of action of SRJ09.

This computational study reflects a broader scientific impetus to harness natural products for epigenetic therapy in blood disorders. HDAC inhibitors, historically explored in oncology, are now revealing potential in modulating gene expression patterns pertinent to genetic anemia. The reported interaction of SRJ09 with HDAC2 paves the way for targeted fetal hemoglobin induction, a strategy anticipated to mitigate the clinical manifestations of beta thalassemia and improve patient outcomes.

Moreover, the stable binding of SRJ09 within the catalytic pocket of HDAC2 is visually and quantitatively comparable to known synthetic inhibitors, indicating that natural derivatives might rival or complement traditional synthetic drugs. This discovery also supports sustainable pharmacology, as the derivation from a widely available plant reduces dependency on costly chemical synthesis and enhances accessibility in resource-constrained regions where beta thalassemia prevalence is high.

Looking forward, the integration of computational and experimental workflows may accelerate the translation of SRJ09 from bench to bedside. Investigating its cellular uptake, target engagement, and specificity against other HDAC isoforms will refine its therapeutic profile. In addition, toxicity profiling and metabolism studies will delineate safety margins indispensable for clinical application.

In summary, the computational insights into SRJ09’s interaction with HDAC2 represent a pivotal advancement in β-thalassemia research. This study not only identifies a promising natural molecule but also exemplifies the power of combining natural product chemistry with state-of-the-art computational pharmacology. By targeting epigenetic regulators to induce fetal hemoglobin, SRJ09 and its analogues may herald a new class of treatments that are both effective and derived from nature’s bounty.

Subject of Research: Beta Thalassemia therapeutics targeting Histone Deacetylase 2 inhibition using natural compounds

Article Title: Computational Insights into the Interactions of Andrographolide Derivative SRJ09 with Histone Deacetylase for the Management of Beta Thalassemia

News Publication Date: 14-Jan-2026

Web References:
https://www.xiahepublishing.com/journal/jerp
http://dx.doi.org/10.14218/JERP.2025.00039

Keywords: Pharmacology, Beta Thalassemia, HDAC2 Inhibition, Andrographolide, Molecular Docking, Molecular Dynamics, Epigenetic Therapy, Natural Products, Fetal Hemoglobin Induction, ADME, Computational Drug Discovery